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Glucose uptakeInsulin stimulates trafﬁcking of GLUT4 to the cell surface for glucose uptake into target cells, and
phosphorylation of Ser703 of the Na+/H+ exchanger NHE1, which activates proton efﬂux. The latter has
been proposed to facilitate optimal glucose uptake into cardiomyocytes. We found that the insulin-
stimulated phosphorylation of Ser703 of NHE1 is mediated by p90RSK but not directly coupled to glucose
uptake in 3T3-L1 adipocytes in the short-term. Inhibiting Erk1/2 activation prevented NHE1 phosphorylation
but not glucose uptake in 3T3-L1 adipocytes. In contrast, both NHE1 phosphorylation and insulin-stimulated
uptake of glucose into 3T3-L1 adipocytes were blocked by inhibitors of the N-terminal kinase domain of
p90RSK, namely BI-D1870 and SL0101, but not the FMK inhibitor of the C-terminal kinase domain of p90RSK,
though in our hands FMK did not inhibit p90RSK in 3T3-L1 adipocytes. Further experiments were consistent
with phosphorylation of AS160 by PKB/Akt mediating insulin-stimulated trafﬁcking of GLUT4 to the plasma
membrane. BI-D1870 and SL0101 however, inhibited glucose uptake without blocking GLUT4 translocation.
While BI-D1870 partially inhibited insulin-stimulated PKB activation in these cells, this only partially
inhibited AS160 phosphorylation and did not block GLUT4 trafﬁcking, suggesting that p90RSK might regulate
glucose transport after GLUT4 translocation. Moreover, BI-D1870 also prevented PMA-induced glucose
transport in 3T3-L1 adipocytes further suggesting a role for p90RSK in regulating uptake of glucose into the
cells. Kinetic experiments are consistent with SL0101 being a direct competitor of 2-deoxyglucose entry into
cells, and this compound might also inhibit uptake of glucose into cells via inhibiting p90RSK, as revealed by
comparison with the inactive form of the inhibitor. Taken together, we propose that BI-D1870 and SL0101
might exert their inhibitory effects on glucose uptake in 3T3-L1 adipocytes at least partially through a
p90RSK dependent step after GLUT4 becomes associated with the plasma membrane.e name TBC1D4); AMPK, AMP
main; GAP, GTPase activating
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Discovered almost a century ago, insulin regulates numerous
cellular activities including entry of glucose into cells, a process whose
deregulation is linked to type II diabetes. The insulin-induced uptake
of glucose into cells in peripheral tissues such as skeletal muscles and
fat tissues is mainly facilitated by glucose transporter 4 (GLUT4),
which moves from the GLUT4 storage vesicles (GSV) in the cytosol to
the cell surface upon insulin stimulation [1]. Over the last decade,
great advances have been made towards understanding how insulin
regulates GLUT4 trafﬁcking, and a large body of studies show thatphosphoinositide 3-kinase (PI 3-kinase) and the PKB pathway are
essential in insulin-stimulated control of GLUT4 translocation
(reviewed by [2]). In the past few years, the Rab GTPase activating
protein (RabGAP) AS160 has emerged as a key PKB substrate in
controlling GLUT4 trafﬁcking [3,4]. The RabGAP activity of AS160
towards Rabs 8A, 10 and/or 14 on GSVs is required to retain GLUT4
within the cytosol in the basal state [3,5]. Upon insulin stimulation,
active PKB can phosphorylate AS160 atmultiple sites and promote 14-
3-3 binding to the phosphorylated AS160, which is proposed to
inactivate the RabGAP activity of AS160 and/or promote the
dissociation of AS160 from GSVs [3,6,7]. Consequently, the Rabs that
are substrates for AS160 are thought to become loaded with GTP and
promote trafﬁcking of GSVs for docking onto and fusion with the
plasmamembrane, where GLUT4 facilitates uptake of glucose into the
cells. AS160 is also phosphorylated by AMPK during exercise in
skeletal muscles [8–10], though a related RabGAP named TBC1D1 is a
better AMPK substrate [11]. The relative roles of AS160 and TBC1D1 as
convergence points in the integration of insulin/PKB and exercise/
AMPK signals in regulating GLUT4 trafﬁcking are a current focus of
attention.
1985S. Chen, C. MacKintosh / Cellular Signalling 21 (2009) 1984–1993In addition to PKB and AMPK, p90 ribosomal protein S6 kinase
(p90RSK) can also phosphorylate AS160 in vitro, as well as in HEK293
cells in response to PMA [7]. Four p90RSK isoforms are present in
human, all of which contain two kinase domains, the N-terminal
kinase domain (NTKD) and the C-terminal kinase domain (CTKD)
joined by a linker region [12]. Many stimuli such as PMA and growth
factors can activate p90RSK, among which the PMA-induced activa-
tion of p90RSK is well deﬁned, involving two upstream kinases Erk1/2
and PDK1 in sequential action. Upon PMA stimulation, Erk1/2
becomes activated, docks onto p90RSK via its C-terminus and
phosphorylates Thr577 in the CTKD and Thr365 in the linker region.
Phosphorylation of Thr577 activates the CTKD, which autopho-
sphorylates Ser386 in the linker region and creates a docking site
for PDK1. PDK1 phosphorylates Ser227 and activates the NTKD, which
phosphorylates all the known p90RSK substrates [12,13]. The
activation mechanisms for p90RSK are context dependent however.
For instance, autoactivation by the CTKD is dispensable for lipopoly-
saccharide-induced p90RSK activation [14], and insulin activates
Erk1/2 in 3T3-L1 adipocytes, but not in all cell types [15]. Inhibitors of
p90RSK inhibitors have been developed, including BI-D1870 and
SL0101 that target the NTKD [16,17] and FMK that targets the CTKD
[18]. These small molecules provide useful tools to study the functions
of p90RSK that are not yet well understood.
Here, we therefore aimed to determine whether p90RSK has any
role in the insulin-stimulated uptake of glucose into 3T3-L1
adipocytes. One relatively well-deﬁned substrate of p90RSK is the
ubiquitously-expressed Na+/H+ exchanger NHE1, which is phos-
phorylated and activated by p90RSK on Ser703 in cells stimulated
with various agonists such as growth factors and phorbol esters, and
in hearts undergoing ischemia and reperfusion injury [19,20]. In
cardiomyocytes, NHE1 can facilitate optimal activation of glucose
transport upon insulin stimulation [21,22]. We therefore compared
the roles of p90RSK, and effects of p90RSK inhibitors, on phosphor-
ylation of NHE1, phosphorylation of AS160 and insulin-stimulated
glucose uptake in 3T3-L1 adipocytes. We also examined whether or
not glucose uptake depends on NHE1 phosphorylation and activation.
2. Materials and methods
2.1. Materials
Recombinant human insulin was from Novo Nordisk (Denmark),
phenformin and phorbol ester phorbol 12-myristate 13-acetate
(PMA) from Sigma-Aldrich and 5-aminoimidazole-4-carboxamide-
1-beta-D-ribofuranoside (AICAR) from Toronto Research Chemicals
(North York, ON, Canada). LY294002 was from Promega, SL0101 from
Toronto Research Chemicals, wortmannin from Sigma-Aldrich, and
SB203580 and SP600125 from Calbiochem. BI-D1870, PD184356,
AS601245, Birb0796, A769662 and SHN799 (the inactive form of
SL0101; 4′,5,7-trimethoxy-SL0101 [23]) were synthesized by Natalia
Shpiro in the Division of Signal Transduction Therapy at the University
of Dundee. Microcystin-LR was from Linda Lawton (Robert Gordon's
University, Aberdeen), protease-inhibitor cocktail tablets (no.
1697498) from Roche, tissue culture reagents and precast SDS-
polyacrylamide gels from Invitrogen. Protein G-Sepharose and other
chromatographic matrices were from GE-Healthcare. All other
chemicals were from BDH Chemicals or Sigma-Aldrich.
2.2. Antibodies
Sheep antibodies against AS160 are as described in Geraghty et al.
[7] and sheep antibodies against RSK2 in Collins et al. [24]. The
antibody that recognises the phosphorylated Ser703 on NHE1 was
raised using the synthetic peptide: SRARIGS*DPLAYE (residues 697 to
709 of human NHE1 where S* represents phosphorylated Ser703).
The antibody that recognises IRAP protein was raised in sheep usingGST-IRAP (residues 1 to 109) fusion protein. The pan-14-3-3 antibody
was K-19 from Santa Cruz, the antibodies that recognise phosphor-
ylated Thr172 on AMPK, phosphorylated Thr308 and Ser473 on PKB,
phosphorylated Thr202/Tyr204 on Erk1/2, phosphorylated Ser21/9 on
GSKα/β, phosphorylated Tyr612 and Ser307 on IRS-1, anti-phospho
(Ser/Thr)-Akt/PKB substrate (PAS) antibody, anti-PKB and anti-Erk1/
2 were from Cell Signaling Technology, and the antibody that
recognises phosphorylated Ser80 on human acetyl-CoA carboxylase
(ACC) (pSer79 on the rat protein) was from Millipore. The antibody
that recognises phosphorylated Ser227 on p90RSK2 was from Abcam
and the antibodies that recognise NHE1 and ﬂotillin-1 were from
Santa Cruz.
2.3. Cell culture, stimulations, lysis and immunoprecipitations
3T3-L1 adipocytes were maintained as ﬁbroblasts and differenti-
ated as described [25]. Brieﬂy, the differentiation was initiated by
adding insulin, isobutylmethylxanthine (IBMX) and dexamethasone
in the culture media after 3T3-L1 ﬁbroblasts were cultured to near
conﬂuence. Four days later, IBMX and dexamethasone were left out of
the culture media. After a further four days, insulin was removed from
the culture media and the cells were cultured for four days before
experiments. 3T3-L1 adipocytes were serum-starved for 4 h, stimu-
lated for 30 min with or without 100 nM insulin. Where indicated,
cells were incubated with LY294002 (LY; 100 µM for 1 h), wortman-
nin (WM; 100 nM for 1 h), Akti1/2 (10 µM for 1 h), PD184352 (2 µM
for 30 min), Birb0796 (0.1 µM for 1 h), AS601245 (5 µM for 1 h), BI-
D1870 (10 µM for 30 min), SL0101 (100 µM for 2 h) and FMK (3 µM
for 90 min) prior to stimulation with insulin. Where indicated, cells
were treated with AICAR (2 mM for 60 min), A769662 (50 µM for
60 min), phenformin (2 mM for 60 min) and PMA (100 ng/ml for
30 min). Where indicated, cells were incubated with Gö6983 (1 µM
for 30 min) and BI-D1870 (10 µM for 30 min) prior to stimulation
with PMA. Unless stated, the stimulation was carried out in DMEM
medium. After stimulation, the mediumwas aspirated, and cells lysed
in 0.3 ml ice cold lysis buffer (50 mM Tris–HCl (pH 7.4), 1 mM EDTA,
1 mM EGTA, 1% (w/v) Triton X-100, 1 mM sodium o-vanadate, 10 mM
sodium glycerophosphate, 50 mM NaF, 5 mM sodium pyrophosphate,
0.27 M sucrose, 2 µM microcystin-LR, 1 mM benzamidine, 0.1% (v/v)
2-ME and complete proteinase inhibitor mixture (Roche; 1 tablet per
50 ml). Lysates were clariﬁed by centrifugation, snap frozen in liquid
N2 and stored at −80 °C until analysis. Protein concentrations were
determined with Bradford reagent (Perbio).
Endogenous AS160, p90RSK2 and NHE1 were precipitated with
anti-AS160 (4 µg antibody/mg lysate protein), anti-p90RSK2 (4 µg
antibody/mg) and anti-NHE1 (2 µg antibody/mg), respectively.
Brieﬂy, lysate was incubated with the antibody at 4 °C for 1 h, 30 µl
of a 50% suspension of protein G-Sepharose in lysis buffer added and
incubation continued for a further hour at 4 °C. The suspension was
centrifuged at 12,000×g for 1 min to sediment between washes. The
immunoprecipitates were eluted in SDS sample buffer.
2.4. Subcellular fractionation of adipocytes
Subcellular fractionation of 3T3-L1 adipocytes was carried out as
described to obtain plasma membrane (PM), high density micro-
somes (HDM), and the low density microsomes (LDM) containing
GLUT4 vesicles [4].
2.5. 14-3-3 overlays and Western blots
After SDS-PAGE, proteins were transferred onto nitrocellulose
membranes that were subsequently blocked with 5% milk solution
and immunoblotted at 4 °C for 16 h using the indicated antibodies at
1 µg/ml. Detection was performed using horseradish-peroxidase-
conjugated secondary antibodies (Promega) and ECL® (enhanced
1986 S. Chen, C. MacKintosh / Cellular Signalling 21 (2009) 1984–1993chemiluminescence reagent; Amersham Biosciences). Direct binding
of 14-3-3 to protein on nitrocellulose membranes was carried out
using DIG-labelled BMH1/2 (two yeast 14-3-3 isoforms), followed by
a horseradish-peroxidase-conjugated anti-DIG antibody [26].
2.6. Glucose uptake assay
Glucose uptake assays were performed as described [25]. Brieﬂy,
3T3-L1 adipocytes were incubatedwith protein kinase inhibitors prior
to stimulation with insulin. After stimulation the cells were washed
and incubated with the HBS uptake buffer (20 mM Hepes, 140 mM
NaCl, 5 mMKCl, 2.5 mMMgSO4, 1 mMCaCl2, pH 7.4) containing 10 µM
2-deoxyglucose (2-DOG) and 1 µCi/ml 3H-2-DOG for 10 min. The cells
were lysed in NaOH and the lysates were used for scintillation
counting and determination of protein concentration. The uptake rates
were normalised with the basal uptake rate in each experiment.
2.7. Immunocytochemistry
Plasmamembrane expression of GLUT4 was determined in 3T3-L1
adipocytes under non-permeabilizing conditions. After differentia-Fig. 1. Effects of inhibitors targeting MAPK pathways on NHE1 phosphorylation, glucose u
adipocytes were stimulated with 100 nM insulin in the presence or absence of p90RSK in
inhibitor Birb0796 alone or in combination. A. Phosphorylation of NHE1 immunoprecipi
recognises phosphorylated Ser703. B. NHE1 was immunoprecipitated from lysates of unstim
on NHE1 was determined using the phospho-speciﬁc antibody that recognises phosphorylat
present as fold increases compared to the basal uptake rate. a.u. arbitrary unit. D. p90RSK2
using the phospho-speciﬁc antibodies that recognise phosphorylated Ser227, Thr365, Ser38
the phosphorylation of PKB and Erk1/2 (pThr308-PKB and pThr202/Tyr204-Erk1/2, respecttion, 3T3-L1 adipocytes grown on glass coverslips were further
cultured in serum-freemedium for 4 h and stimulated for 30 minwith
or without 100 nM insulin. Where indicated, cells were incubated
with BI-D1870 (10 µM for 30 min) and SL0101 (100 µM for 2 h) prior
to stimulation with insulin. Cells ﬁxed in paraformaldehyde were
sequentially incubated with anti-GLUT4 (Abcam) antibody and Alexa
Fluor®-conjugated secondary antibodies (Invitrogen). After decora-
tion with the antibodies, slides were mounted with Hydromount
(National Diagnostics), observed with a Leica confocal microscope,
and representative images are shown.
3. Results
3.1. p90RSK mediates insulin-stimulated NHE1 phosphorylation in
3T3-L1 adipocytes
In 3T3-L1 adipocytes, NHE1 was phosphorylated at Ser703 in
response to insulin (Fig. 1A). This insulin-stimulated phosphorylation
was blocked by PD184352, which inhibits the activation of Erk1/2, and
by BI-D1870, which inhibits the N-terminal kinase domain of p90RSK.
Consistent with the Erk1/2–p90RSK pathway being responsible forptake and phosphorylation of p90RSK, PKB and Erk1/2 in 3T3-L1 adipocytes. 3T3-L1
hibitor BI-D1870, Erk1/2 inhibitor PD184352, JNK inhibitor AS601245 and p38MAPK
tated from the crude lysates was assessed using the phospho-speciﬁc antibody that
ulated cells and phosphorylated in vitro by p90RSK and PKB. Phosphorylation of Ser703
ed Ser703. C. Uptake of glucose into 3T3-L1 adipocytes was measured and the data were
was immunoprecipitated from the cell lysates and its phosphorylation was determined
6 and Thr577. In the bottom three panels, cell lysates (40 μg) were analysed to monitor
ively). 14-3-3 proteins act as the loading control.
Fig. 2. Effects of p90RSK inhibitor BI-D1870 on phosphorylation of AS160 and NHE1 in
3T3-L1 adipocytes in response to insulin or PMA. 3T3-L1 adipocytes were stimulated
with 100 nM insulin in the presence or absence of the PI 3-kinase inhibitor LY294002
and p90RSK inhibitor BI-D1870, and PMA in the presence or absence of PKC inhibitor
Gö6983 and p90RSK inhibitor BI-D1870, and AMPK activators A769662, AICAR and
phenformin. In the upper nine panels, AS160 was immunoprecipitated from cell lysates
and its phosphorylation was analysed using the phospho-speciﬁc antibodies that
recognise phosphorylated Ser318, Ser341, Ser570, Ser588, Thr642 and Ser751. The 14-
3-3 binding capacity was determined on the immunoprecipitated AS160 using a 14-3-3
overlay assay. In the middle two panels, phosphorylation of NHE1 was assayed on the
NHE1 protein immunoprecipitated from the cell lysates using the phospho-speciﬁc
antibody that recognises phosphorylated Ser703. In the bottom six panels, cell lysates
(40 μg) were analysed to monitor the phosphorylation of PKB, Erk1/2, ACC and AMPK
(pThr308-PKB, pSer473-PKB, pThr202/Tyr204-Erk1/2, pSer79-ACC and pThr172-
AMPK, respectively). Total Erk1/2 proteins act as the loading control.
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precipitated from cell lysates could be phosphorylated in vitro by
RSK1 but not PKB (Fig. 1B).
3.2. BI-D1870 inhibits insulin-stimulated glucose uptake in 3T3-L1
adipocytes
To investigate whether NHE1 activation plays any role in insulin-
induced glucose uptake in 3T3-L1 adipocytes, the cells were pre-
treated with BI-D1870, PD184352, AS601245 and Birb0796, stimu-
lated with insulin and subsequently subject to glucose uptake assay
(Fig. 1C). PD184352 had no effect on insulin-induced glucose uptake
in 3T3-L1 adipocytes, despite its strong inhibitory effect on NHE1
phosphorylation (Fig. 1A), indicating that NHE1 activation might not
play a supportive role in glucose uptake under this experimental
condition. Interestingly, BI-D1870 and the c-Jun NH2-terminal kinase
(JNK) inhibitor AS601245 strongly inhibited insulin-induced glucose
uptake in 3T3-L1 adipocytes (Fig. 1C). When used in combination, BI-
D1870 and AS601245 had stronger inhibitory effects on glucose
uptake compared to each inhibitor alone. The p38MAPK inhibitor
Birb0796 did not affect insulin-induced glucose uptake in 3T3-L1
adipocytes (Fig. 1C).
The phosphorylation of RSK2, PKB and Erk1/2 was analysed in
order to gain insights into the mechanisms of BI-D1870 on glucose
uptake (Fig. 1D). Insulin promoted the phosphorylation of RSK2 on all
four sites examined, namely Ser227, Thr365, Ser386 and Thr577. Pre-
treatment with BI-D1870 enhanced the insulin-induced phosphory-
lation of Ser386 and Thr577, whereas this compound decreased the
phosphorylation of Thr365. Preincubationwith PD184352 blocked the
insulin-induced phosphorylation of RSK2 on the four sites. In contrast,
AS601245 and Birb0796 had no effect on RSK2 phosphorylation in
3T3-L1 adipocytes. For PKB, both BI-D1870 and AS601245 decreased
the activating phosphorylation of Thr308, whereas PD184352 and
Birb0796 did not affect phosphorylation of PKB. Consistent with the
effects on RSK2 phosphorylation, pre-treatment with PD184352
blocked, while BI-D1870 slightly enhanced, the insulin-induced
phosphorylation of Erk1/2 (Fig. 1D).
3.3. BI-D1870 decreases phosphorylation of and 14-3-3 binding to AS160
upon insulin stimulation in 3T3-L1 adipocytes
The strong inhibitory effect of BI-D1870 on glucose uptake led us
to investigate its effects on the GLUT4-trafﬁcking regulator AS160 [3].
In 3T3-L1 adipocytes, insulin induced the phosphorylation of AS160
on all the seven sites analysed, namely Ser318, Ser341, Ser570,
Ser588, Thr642, Ser666 and Ser751, and increased the interaction of
AS160 with 14-3-3 (Fig. 2). Pre-treatment with the PI 3-kinase
inhibitor LY294002 blocked the insulin-induced phosphorylation of
AS160 and its interaction with 14-3-3 proteins. Pre-treatment with
BI-D1870 decreased the phosphorylation of AS160 on several sites
including Ser318, Ser341, Ser570, Ser588 and Ser666, and also
decreased 14-3-3 binding to AS160. Since BI-D1870 not only blocked
RSK but also moderately inhibited PKB in insulin-stimulated 3T3-L1
adipocytes (Fig. 2), we used PMA stimulation to investigate whether
RSK can phosphorylate AS160 in 3T3-L1 adipocytes because PMA did
not induce PKB activation (Fig. 2). PMA induced weaker phosphor-
ylation of AS160 only on three sites, Ser341, Ser588 and Ser751, but
stronger phosphorylation of NHE1 as compared to insulin (Fig. 2). The
PMA-induced AS160 phosphorylation was blocked by the non-
speciﬁc PKC inhibitor Gö6983 as well as BI-D1870, indicating that
RSK can phosphorylate AS160 on the three sites, Ser341, Ser588 and
Ser751 in 3T3-L1 adipocytes. Interestingly, the combination of PMA
and BI-D1870 strongly activated AMPK as evidenced by the
phosphorylation of AMPK alpha subunit and AMPK substrate ACC
(Fig. 2). Though AMPK has been proposed to be an upstream kinase
for AS160 [8], the PMA/BI-D1870-activated AMPK had no effect onAS160 phosphorylation in 3T3-L1 adipocytes, consistent with the lack
of effect of three AMPK activators, A769662, AICAR and phenformin
on phosphorylation of AS160 (Fig. 2). In control assays, all three AMPK
activators increased phosphorylation of the well-deﬁned AMPK
substrate acetyl-CoA carboxylase (ACC) (Fig. 2).
3.4. BI-D1870 partially inhibits PKB without affecting the signalling
pathway upstream PI 3-kinase in 3T3-L1 adipocytes
BI-D1870 did not affect EGF-induced PKB phosphorylation in Rat-2
cells [16] and also did not inhibit IGF1-induced PKB activation in
HEK293 cells (data not shown). The inhibitory effect of BI-D1870 on
insulin-induced PKB activation in 3T3-L1 adipocytes was therefore
intriguing and further addressed in these cells. For comparison, the
PKB inhibitor Akti1/2 and PI 3-kinase inhibitors wortmannin and
LY294002 were used to inhibit the PI 3-kinase–PKB pathway. Pre-
treatment with BI-D1870 strongly suppressed the insulin-induced
1988 S. Chen, C. MacKintosh / Cellular Signalling 21 (2009) 1984–1993glucose uptake in 3T3-L1 adipocytes (Fig. 3A) and decreased insulin-
induced PKB phosphorylation on both Thr308 and Ser473 (Fig. 3B).
The PI 3-kinase inhibitor LY294002 and PKB inhibitor Akti1/2completely blocked insulin-stimulated PKB phosphorylation. IRS-1
phosphorylation and p85 recruitment upon insulin stimulation were
then surveyed to address whether BI-D1870 affected the signalling
Fig. 4. Effect of BI-D1870 on PMA-induced glucose uptake in 3T3-L1 adipocytes. Glucose
uptake rates were measured in 3T3-L1 adipocytes stimulated with 100 ng/ml PMA in
the presence or absence of p90RSK inhibitor BI-D1870. The data were present as fold
increases compared to the basal uptake rate.
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with BI-D1870 did not affect the tyrosine phosphorylation or Ser307
phosphorylation on IRS-1, or the engagement of p85. In contrast, both
LY294002 and Akti1/2 inhibited Ser307 phosphorylation though they
did not affect the tyrosine phosphorylation on IRS1-1 and the
recruitment of p85 (Fig. 3B). Therefore, these results provide no
explanation for the effect of BI-D1870 inhibiting phosphorylation of
PKB in terms of the signalling pathway upstream of PI 3-kinase in 3T3-
L1 adipocytes.
In the dose response assay, 1 µM Akti1/2 completely inhibited
glucose uptake in 3T3-L1 adipocytes (Fig. 3C). At this concentration,
the inhibitor strongly decreased PKB phosphorylation on both Thr308
and Ser473, and also blocked GSK3 phosphorylation (Fig. 3D). The
inhibitory effects of BI-D1870 on glucose uptake in 3T3-L1 adipocytes
correlated with the reduction of PKB phosphorylation but not GSK3
phosphorylation in the dose response assay (Fig. 3C and D). At 10 µM,
BI-D1870markedly decreased PKB phosphorylation but had no effects
on GSK3 phosphorylation (Fig. 3D). When a physiological concentra-
tion of insulin (1.7 nM) was used to stimulate 3T3-L1 adipocytes even
1 µM BI-D1870, which did not affect PKB phosphorylation, decreased
glucose transport into the cells (Fig. 3E).
3.5. BI-D1870 prevented PMA-induced glucose uptake in 3T3-L1
adipocytes
To further rule out the possibility that PKB mediated the effect of
BI-D1870 on insulin-stimulated glucose uptake in 3T3-L1 adipocytes,
we used PMA instead of insulin. PMA is a known activator for glucose
transport but not PKB activation [27]. Though PMA is a weaker
activator for glucose transport than insulin, the phorbol ester induced
>2.5-fold increase in glucose uptake in 3T3-L1 adipocytes (Fig. 4).
Interestingly, pre-treatment with BI-D1870 completely prevented
PMA-induced uptake of glucose into the cells, suggesting that the
effect of BI-D1870 on glucose transport is not mediated by PKB but by
p90RSK in PMA-stimulated, and probably insulin-stimulated, cells.
3.6. Both RSK NTKD inhibitors BI-D1870 and SL0101 but not the CTKD
inhibitor FMK inhibit glucose uptake in 3T3-L1 adipocytes
Since BI-D1870 moderately inhibited PKB in 3T3-L1 adipocytes
however, it is difﬁcult to assess the importance of RSK in regulating
glucose uptake based on this compound alone. Therefore, two
structurally-unrelated RSK inhibitors SL0101 and FMK were included
in the following study. In the glucose uptake assay, both RSK NTKD
inhibitors BI-D1870 and SL0101 markedly inhibited glucose uptake
into the cells while the CTKD inhibitor FMK had no effect on insulin-
induced glucose uptake (Fig. 5A). Unlike BI-D1870, SL0101 did not
affect PKB phosphorylation (Fig. 5B). Interestingly, both BI-D1870 and
SL0101 enhanced the insulin-induced phosphorylation of RSK2 at
Thr577 and Ser386, indicating that a feedback mechanism might
operate when the RSK NTKD activity is inhibited by these two
compounds. Consistent with Fig. 1D, BI-D1870, but not SL0101,
blocked the phosphorylation of Thr365 of RSK2, though this site and
Thr577 are both phosphorylated by Erk1/2. Pre-treatment with FMK
indeed inhibited the phosphorylation of Ser386 indicating thisFig. 3. Comparison of the effects of the PKB inhibitor Akti1/2 and p90RSK inhibitor BI-D1870
3T3-L1 adipocytes. A. Glucose uptake rates were measured in 3T3-L1 adipocytes stimulated w
inhibitor Akti1/2 and p90RSK inhibitor BI-D1870. The data are given as fold increase compa
monitor the phosphorylation of PKB on Thr308 and Ser473 sites. Phosphorylation of IRS-1
phospho-speciﬁc antibodies that recognise phosphorylated Tyr612 and Ser307. Recruitmen
IRS-1. C. Glucose uptake rates weremeasured in 3T3-L1 adipocytes stimulated with 100 nM i
p90RSK inhibitor BI-D1870. a.u. arbitrary unit. D. Cell lysates (40 μg) were analysed to monit
respectively). 14-3-3 proteins act as the loading control. E. Glucose uptake rates were measu
different concentrations of p90RSK inhibitor BI-D1870. a.u. arbitrary unit. F. 3T3-L1 adipocy
with 1.7 nM insulin. Cell lysates (40 μg) were analysed to monitor the Ser473 phosphorylainhibitor worked to inhibit the CTKD in the 3T3-L1 adipocytes, as
has been reported in other cell types. However, the inhibition of
Ser386 phosphorylation by FMK did not affect the phosphorylation of
Ser227 in the NTKD of RSK (Fig. 5B). Consistent with this ﬁnding, FMK
did not inhibit the phosphorylation of NHE1 at Ser703, indicating that
it did not inhibit the RSK NTKD (Fig. 5B). In contrast, both RSK NTKD
inhibitors, BI-D1870 and SL0101 decreased the insulin-induced
phosphorylation of NHE1 at Ser703 (Fig. 5B).
3.7. BI-D1870 and SL0101 do not alter insulin-induced GLUT4 trafﬁcking
to the plasma membrane
As shown in Fig. 6A, the insulin-induced expression of GLUT4 on
the plasma membrane was unaffected by BI-D1870 and SL0101.
Neither was the redistribution of the GLUT4 vesicle marker IRAP from
low density microsomes to plasma membrane affected by these two
inhibitors (Fig. 6B). These data suggested that the defect caused by BI-
D1870 and SL0101 occurred at a step after GLUT4 fusion with the
plasma membrane.
3.8. SL0101 might directly affect the GLUT4 transporter
To test whether BI-D1870 and SL0101 directly interfered with the
GLUT4 transporter, cells were stimulated with insulin and these two
compounds were added only during the 10-min period of the glucose
uptake assay. As shown in Fig. 7A, BI-D1870 in the uptake assay only
caused a moderate reduction of glucose uptake, whereas addition of
SL0101 in the uptake media completely blocked the uptake of glucose
into the cells, indicating that SL0101 might exert its effects at least
partially through the GLUT4 transporter. Addition of a range of
concentrations of SL0101 from 0.5 µM to 100 µM in the uptake media
prevented insulin-induced glucose uptake in a dose-dependenton glucose uptake, p85 recruitment and phosphorylation of PKB, IRS-1 and GSK3α/β in
ith 100 nM insulin in the presence or absence of PI 3-kinase inhibitor wortmannin, PKB
red to the basal uptake rate. a.u. arbitrary unit. B. Cell lysates (40 μg) were analysed to
was analysed on the IRS-1 protein immunoprecipitated from the cell lysates using the
t of the p85 subunit of PI 3-kinase to IRS-1 was analysed in the immunoprecipitates of
nsulin in the presence or absence of different concentrations of PKB inhibitor Aki1/2 and
or the phosphorylation of PKB and GSK3α/β (pThr308, pSer473 and pSer21/9-GSKα/β,
red in 3T3-L1 adipocytes stimulated with 1.7 nM insulin in the presence or absence of
tes were pre-treated with various concentrations of BI-D1870 prior to the stimulation
tion of PKB.
Fig. 5. Effects of p90RSK NTKD inhibitors BI-D1870 and SL0101 and CTKD inhibitor FMK
on glucose uptake and phosphorylation of PKB, p90RSK and NHE1 in 3T3-L1 adipocytes.
3T3-L1 adipocytes were stimulated with 100 nM insulin in the presence or absence of
p90RSK NTKD inhibitors BI-D1870 and SL0101, and CTKD inhibitor FMK. A. Uptake of
glucose into 3T3-L1 adipocytes was measured and the data were present as fold
increases compared to the basal uptake rate. a.u. arbitrary unit. B. In the top ﬁve panels,
phosphorylation of p90RSK2 was analysed on the p90RSK2 proteins immunoprecipi-
tated from the cell lysates using the phospho-speciﬁc antibodies that recognises
phosphorylated Ser227, Thr365, Ser386 and Thr577. In the middle two panels,
phosphorylation of the NHE1 protein immunoprecipitated from the cell lysates was
analysed using the phospho-speciﬁc antibody that recognises phosphorylated Ser703.
In the bottom two panels, phosphorylation of PKB on Thr308 was determined in the cell
lysates, with 14-3-3 as the loading control.
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The inhibitory effect of SL0101 on glucose uptake was greater when it
was used to pre-treat the cells in the glucose uptake media compared
with its addition to the growth media (Fig. 7C). In contrast, while the
uptake of glucose into the cells was decreased by SHN799 (a variant of
SL0101 that does not inhibit p90RSK), pre-treatment with SHN799 inthe uptake media did not enhance its inhibitory effect on glucose
uptake. These ﬁndings indicate that SL0101 inhibits insulin-stimulat-
ed glucose uptake by two mechanisms, one via p90RSK and the other
by directly competing with glucose for uptake into cells.
4. Discussion
Here we show that p90RSK mediates insulin-induced phosphor-
ylation of Ser703 on NHE1 as evidenced by using the inhibitors of the
Erk1/2–p90RSK signalling cascade (Fig. 1A). These data are consistent
with the cumulative evidence that p90RSK is the upstream kinase
phosphorylating NHE1 in response to various other physiological and
pathophysiological stimuli such as alpha1-adrenoceptor agonists, and
cardiac and neuronal ischemia–reperfusion [20,28–30]. p90RSK-
mediated phosphorylation of NHE1 enhances its interaction with
14-3-3 proteins, increases its exchanger activity and results in cellular
alkalinization [28]. Recent evidence suggests that NHE1-mediated
cytosol alkalinization in response to insulin is required for optimal
activation of glucose transport in cardiomyocytes [21] and AICAR can
reduce uptake of glucose into the cardiomyocytes through the
inhibition of NHE1 independent of AMPK [22]. AICAR also inhibits
insulin-stimulated glucose uptake in 3T3-L1 adipocytes [31]. There-
fore, it was tempting to hypothesise that NHE1 might play a similar
role in supporting optimal glucose transport in 3T3-L1 adipocytes, as
in cardiomyocytes. However, the Erk1/2 inhibitor, PD184352, blocked
insulin-induced phosphorylation of Ser703 on NHE1 that is required
for NHE1 activation without affecting the glucose transport into 3T3-
L1 adipocytes (Fig. 1A and C), which suggests that NHE1 does not
facilitate glucose transport into 3T3-L1 adipocytes, at least in the
short-term.
In contrast to the Erk1/2 inhibitor PD184352, both RSK NTKD
inhibitors, BI-D1870 and SL0101, prevented insulin-stimulated up-
take of glucose into 3T3-L1 adipocytes as well as the phosphorylation
of Ser703 on NHE1 (Fig. 1A and C). Given that PD184352 prevented
the insulin-stimulated phosphorylation of p90RSK2 and NHE1 in 3T3-
L1 adipocytes (Fig. 1), this was the ﬁrst indication that the effects of
the RSK inhibitors on glucose uptake might not be explicable solely by
effects on the target kinase. Unlike Rat-2 and HEK293 cells where BI-
D1870 has no effect on PKB activation [16] (data not shown), this
inhibitor reduced the PKB activation in a dose-dependent manner in
3T3-L1 adipocytes (Figs. 1D and 2), suggesting some cell speciﬁc
factor might be present in 3T3-L1 adipocytes rendering the PI 3-
kinase–PKB pathway in these cells susceptible to BI-D1870. Despite
partial inhibition of PKB by 10 µM BI-D1870, GLUT4 trafﬁcking to the
plasma membrane was unimpaired by this concentration of BI-D1870
in the 3T3-L1 adipocytes as evidenced by the GLUT4 staining and the
redistribution of IRAP (Fig. 6) that co-translocates with GLUT4 [32],
suggesting that down-regulation of PKB by BI-D1870 might not fully
account for its inhibition of glucose transport into the cells. Consistent
with this notion, down-regulation of PKB activation by BI-D1870 had
no effect on insulin-induced GSK3 phosphorylation whereas inhibi-
tion of PKB by Akti1/2 blunted GSK3 phosphorylation, suggesting that
the degree of inhibition of PKB by BI-D1870 might not be sufﬁcient to
affect the downstream targets of PKB. Moreover, even a low
concentration of BI-D1870 (1 µM) that did not inhibit PKB activation
could reduce glucose uptake stimulated by a physiological concen-
tration of insulin (Fig. 3E). Furthermore, BI-D1870 also prevented
glucose transport induced by PMA that does not activate PKB (Figs. 2
and 4). Insulin-induced GLUT4 trafﬁcking to the plasma membrane
involves multiple steps, the recruitment and/or docking of GLUT4
vesicles to within 250 nm of the plasma membrane and the post-
docking steps including the priming and fusion of GLUT4 vesicles with
the plasmamembrane [33]. PI 3-kinase activities are required for both
docking and post-docking steps while PKB activation is only essential
for the docking step [34]. Consistent with the role of PKB in the
docking step of GLUT4 trafﬁcking, its substrate AS160 also only
Fig. 6. Effects of p90RSK inhibitors on insulin-induced redistribution of GLUT4 and IRAP in 3T3-L1 adipocytes. A. 3T3-L1 adipocytes were stimulated with 100 nM insulin in the
presence or absence of p90RSK inhibitors 10 μM BI-D1870 and 100 μM SL0101, subsequently ﬁxed and used for immunocytochemistry assay. GLUT4 expression on plasma
membranes was determined using anti-GLUT4 antibody (Abcam) and Alexa Fluor®-conjugated secondary antibody (Invitrogen) under impermeable staining conditions. The images
were taken using a Leica confocal microscope. a, basal; b, insulin; c, BI-D1870+insulin; d, SL0101+insulin. B. 3T3-L1 adipocytes were stimulated with 100 nM insulin in the
presence or absence of p90RSK NTKD inhibitors BI-D1870 and SL0101, and CTKD inhibitor FMK. The cells were subsequently fractionated to obtain plasma membrane, high and low
density microsomal membrane fractions (HDM and LDM). IRAP protein in different membrane fractions was detected using anti-IRAP antibody. Flotillin-1 protein acts as the loading
control.
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docking steps [33,35]. Pre-treatment with BI-D1870 did not alter
plasma membrane-bound GLUT4 upon insulin stimulation suggested
that the docking step regulated by PKB might not be affected by this
compound. However, both GLUT4 immunostaining and subcellular
fractionation could not resolve the post-docking steps of GLUT4
trafﬁcking. Therefore, in the present study we could not distinguish
between GLUT4 fused and/or docked with plasma membrane. In the
future, further experimentation with the recently-developed total
internal reﬂection ﬂuorescence (TIRF) microscopy [33,34,36] shall be
carried out to resolve the effect of BI-D1870 on the post-docking steps
of GLUT4 trafﬁcking. Taken together, we propose that BI-D1870 at
least partially exerts its effect on glucose uptake independent of the PI
3-kinase–PKB pathway at a step after GLUT4 docks onto the plasma
membrane, but the effect of BI-D1870 is not explained either by a
direct effect on GLUT4, such as competition with glucose for uptake
via the transporter (Fig. 7A).
Unlike BI-D1870, the other RSK NTKD inhibitor SL0101, a
polyphenolic glycoside, did not affect insulin-induced PKB activation
but did exert its effect on glucose uptake at least partially through the
glucose transporters themselves, since it virtually blunted glucose
entry into the cells when present in the glucose uptake media
(Fig. 7A). Consistent with this proposal, the inactive form of SL0101
moderately inhibited insulin-induced glucose transport into the cells
(Fig. 7C). Switching the incubation media from glucose-containing
DMEM to glucose-free HBS buffer sensitized glucose uptake toinhibition by SL0101 (Fig. 7C), suggesting that this compound might
enter the cells through the glucose transporters. Interestingly, the
same protocol did not sensitize the effect of the inactive form of
SL0101 on glucose uptake (Fig. 7C), suggesting that besides the
glucose transporters a p90RSK dependent step might also contribute
to the effect of SL0101 on glucose transport. Similar to BI-D1870,
SL0101 did not affect the GLUT4 translocation onto the plasma
membrane (Fig. 6), again indicating that the p90RSK dependent step
mediating the inhibition of glucose transport by SL0101 occurs after
GLUT4 moves onto the cell surface. Therefore, we speculate that BI-
D1870 and SL0101 might target a common step through p90RSK in
inhibiting glucose transport into the cells.
A major puzzle therefore is why the Erk1/2 inhibitor PD184352
had no effect on glucose uptake while it could efﬁciently blunt NHE1
phosphorylation through inhibiting p90RSK? It has been reported that
pharmaceutical inhibition of Erk1/2 did not lead to the inhibition of
p90RSK4 in contrast to the other three p90RSK isoforms [37] whereas
BI-D1870 and SL0101 inhibit all the four p90RSK isoforms [16,38].
Maybe all four p90RSKs need to be inactivated before any effect on
glucose uptake can be revealed while only p90RSK1–3 that are
sensitive to Erk1/2 inhibitors mediate NHE1 phosphorylation.
Alternatively, the effect on glucose uptake posed by the p90RSK
inhibitorsmight be different from that exerted by the Erk1/2 inhibitor.
Cumulative evidence suggests that activation of p90RSK by Erk1/2 can
negatively control the Ras–Erk1/2 pathway [39,40]. Consistent with
such negative feedback, both p90RSK inhibitors BI-D1870 and SL0101
Fig. 7. Effects of p90RSK inhibitors on glucose transporters in 3T3-L1 adipocytes. A. Two
protocols were used to assay the effects of p90RSK inhibitors on glucose uptake into
3T3-L1 adipocytes. In protocol I, the cells were pre-treated with the p90RSK inhibitors
BI-D1870, SL0101 and FMK, and stimulated with 100 nM insulin in the last 30 min. The
cells were then washed with uptake buffer twice and used in glucose uptake assays that
ran for 10 min. In protocol II, the cells were stimulated with insulin for 30 min and
washed with uptake buffer twice before glucose uptake assay, and the BI-D1870,
SL0101 and FMK added into the glucose uptake assays. a.u. arbitrary unit. B. 3T3-L1
adipocytes were pre-treated with various concentrations of SL0101 and stimulated
with 100 nM insulin for 30 min. The cells were washed with uptake buffer twice before
assay for glucose uptake. a.u. arbitrary unit. C. 3T3-L1 adipocytes were pre-treated with
various concentrations of SL0101, and its inactive form SHN799, either in DMEMmedia
or in uptake buffer (HBS buffer) and then stimulated with 100 nM insulin for 30 min.
The cells were washed with uptake twice before assay for glucose uptake. a.u. arbitrary
unit.
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(Fig. 1D and data not shown). Since Erk1/2 has numerous other
substrates besides p90RSK, it can be envisioned that the effects of the
p90RSK inhibitors that enhance the Erk1/2 activation through
inactivating p90RSK might differ from those of the Erk1/2 inhibitor
that inactivate both Erk1/2 and p90RSK. However, at the moment we
cannot rule out the possibility that both BI-D1870 and SL0101 exert
their effects on glucose transport independent of p90RSK either
through another unrelated protein kinase or through directly
inhibiting GLUT4 that upon insulin stimulation can be more
susceptible to inhibition by drugs such as SB203580, a p38MAPK
inhibitor [41].
The ﬁnding that SL0101 might enter cells through glucose
transporters is intriguing since this compound has been shown to
selectively inhibit the proliferation of a human breast cancer cell line
but not a normal breast cell line [17]. A high-rate absorption of glucose
through over-expression of glucose transporters in solid tumours
contributes to the abilities of cancer cells to operate a high-rate of
glycolysis [42]. Further elucidation of how SL0101 enters cells will
help in fully understanding the selectivity of SL0101 on the
proliferation of cancer and normal cells and to design drugs with
better selectivity against cancers.
Using various inhibitors we also explored the regulation of
p90RSK2 by insulin in 3T3-L1 adipocytes, which is poorly studied so
far, and revealed some unexpected aspects of insulin-induced
p90RSK2 phosphorylation. Similar to PMA-induced p90RSK phos-
phorylation, the insulin-stimulated phosphorylation of p90RSK2 on
all four sites examined was blunted by the Erk1/2 inhibitor
PD184352 but not the JNK inhibitor AS601245 or the p38MAPK
inhibitor Birb796 (Fig. 1D), which is consistent with Erk1/2 being the
kinase that phosphorylates Thr365 and Thr577 [12]. However, the
p90RSK-NTKD inhibitor BI-D1870 prevented insulin-induced phos-
phorylation of Thr365 on p90RSK though it enhanced the phos-
phorylation of Thr577 through augmented Erk1/2 activation
(Figs. 1D and 5B), indicating that Erk1/2 might not be the upstream
kinase phosphorylating Thr365 in response to insulin in 3T3-L1
adipocytes. The increased Erk1/2 activation by BI-D1870 has been
reported and thought to be due to a feedback control mechanism
[16], which is consistent with ﬁnding that the other p90RSK NTKD
inhibitor SL0101 also enhanced the phosphorylation of Thr577
(Fig. 5B). In contrast to BI-D1870, SL0101 did not blunt the
phosphorylation of Thr365, indicating that the upstream kinase for
Thr365 in response to insulin is Erk1/2–p90RSK independent but BI-
D1870 sensitive. An alternative possibility is that binding to BI-
D1870 renders Thr365 inaccessible to Erk1/2. Consistent with the
p90RSK CTKD being the kinase phosphorylating Ser386, both BI-
D1870 and SL0101 enhanced the phosphorylation of Ser386
presumably by increasing CTKD activity via a higher phosphoryla-
tion of Thr577, and the CTKD inhibitor FMK decreased the
phosphorylation of Ser386 site without affecting NTKD activation
through the phosphorylation of Ser227 (Fig. 6). It remains a puzzle
how PDK1, which must dock onto p90RSK via phosphorylated
Ser386, phosphorylates Ser227 site in the presence of FMK in
response to insulin.
5. Conclusions
Overall, we show in the present study that p90RSK-mediated
NHE1 phosphorylation is not required for insulin-induced glucose
uptake in 3T3-L1 adipocytes in the short-term. However, the p90RSK
inhibitor BI-D1870 prevents glucose entry into cells in response to
insulin as well as PMA in 3T3-L1 adipocytes, probably through
inhibiting a step after GLUT4 docks onto the plasma membrane.
Further dissecting the inhibitory effect on GLUT4 trafﬁcking posed by
BI-D1870 using TIRF microscopy may help to gain more insights into
the regulation of GLUT4 trafﬁcking.
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